ALG-000184 demonstrated a robust multi-log reduction in both serum HBV DNA (approximately 3-4 log10 IU/mL) and HBV RNA (approximately 0.5-3.0 log10 copies/mL) across all evaluated doses in a 28-day period.
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
